A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

Exclusion Criteria

• •Any form of leukemia except for Stage 0 and 1 chronic lymphocytic leukemia (CLL) not requiring treatment in addition to the underlying malignancy
• •Hormonal therapy within the 2 weeks prior to the first dose of study medication. Patients with prostate cancer who are not surgically castrated should remain on GnRH analogues.
• •Patients who are using other investigational agents or who received investigational drugs \</= 4 weeks prior to study treatment start.
• •Pre-existing GI disorders that may interfere with proper absorption of the drug(s), as per investigator discretion.
• •History of allergic reactions attributed to components of the formulated product
• •History of seizure disorders or unstable CNS metastases
• •Any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
• •Patients who must receive CYP2C8 inhibitors, substrates or inducers, strong CYP 3A4 inducers or moderate/strong CYP3A4 inhibitors listed in protocol while on study. Substrates, inducers, and inhibitors listed in protocol must be discontinued 7 or 14 days prior to start of study medication.
• •Evidence of electrolyte imbalance (treatment for correction of electrolyte imbalances is permitted during screening to meet eligibility)
• •Pregnant or breast feeding women
• •HIV-positive patients who are currently receiving combination anti-retroviral therapy
• •Patients with known coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia.
• •Patients receiving oral or parenteral anticoagulants/antiplatelet agents (e.g., chronic daily treatment with aspirin (\> 325 mg/day), clopidogrel, low molecular weight heparin, or subcutaneous anticoagulant prophylaxis). A washout period of at least 7 days prior to the start of study is required. Patients may receive anticoagulant flushes for maintenance of indwelling catheters.
• •Patients who refuse to potentially receive blood products and/or have a hypersensitivity to blood products
• •Part 1 only: Hypersensitivity to posaconazole, or any of the other ingredients, or any other azole antifungal
• •Part 1 and Part 3: Patients who cannot tolerate high-fat and/or full meals.